In two children with atopic dermatitis, routine vaccination with bacillus Calmette-Guerin (BCG) was followed by severe exacerbation of skin disease. If the sequence is cause and effect, a possible mechanism is stimulation of a Th2 lymphocyte cytokine profile by the vaccine, with migration of activated lymphocytes to inflamed skin. In children with active atopic dermatitis, BCG vaccination is best deferred until remission.
The University Department of Child Health at Booth Hall Children's Hospital in Manchester has a special interest in atopic dermatitis (AD). Approximately 250 new patients per year are seen in the setting of a paediatric rather than a dermatology service. The patients are followed up until they improve, and the unit operates a drop-in service to deal with acute exacerbations. One complication that has been noted in this clinic is worsening of skin lesions after bacillus Calmette-Guerin (BCG) vaccination in teenagers with atopic dermatitis. Since the association between worsening of atopic dermatitis and BCG vaccination is not well known, we report two cases. CASE HISTORIES Case I Atopic dermatitis was first noted in this boy at the age of 6 weeks, and was regarded as a reason for withholding both pertussis and measles immunizations. He was under the care of a dermatologist from the age of 1 year, and he required admission to hospital for his dermatitis at the ages of 4, 5 and 10 years (the last admission shortly after referral to our service). Orchidopexy and a right inguinal hernia repair were performed at 1 1 1Y2 years of age. At that time, the skin lesions were confined to the hands, feet, face and chest wall, and were well controlled with Vioform Hydrocortisone ointment (1% hydrocortisone and clioquinol 3%) to the face and mildly affected areas, and Locoid C ointment (hydrocortisone butyrate 0. 1% and chlorquinaldol 3%) on more severe lesions. At 1134 years, BCG was administered to the left arm as part of a routine immunization schedule at school. A week later, eczema flared at the face, wrist and popliteal fossae. Despite treatment with oral flucloxacillin and the above topical steroids, the skin lesions continued to deteriorate and the patient was admitted to hospital 4 weeks after BCG vaccination. On admission, there were widespread severely inflamed skin lesions affecting the face, trunk and limbs, and the patient was very distressed. There was slight improvement with the use of a very potent steroid ointment (clobetasol propionate 0.05%). On the advice of the infectious disease service-because of concern about the possibility of disseminated BCG infection-he was treated for 3 months with isoniazid (6 mg/kg/day) and pyridoxine (10 mg daily). The exacerbation of the skin lesions resolved 31 months after vaccination. He was followed up in the clinic to the age of 14 years, by which time his skin lesions were mild and he was discharged. His case was reported to the Committee on Safety of Medicines.
Case 2
Atopic dermatitis was first noted in this girl at the age of 10 months. An egg and cow's milk free diet was instituted at the age of 3 years. Over the years, cold weather, Chinese herbal therapy, and the consumption of fish, prawns, baked beans, egg and cow's milk were associated with worsening of the skin lesions, whilst holidays in Florida and Pakistan were associated with improvement. By I034 years asthma had developed. She required admission for exacerbations of atopic dermatitis at the ages of 6, 8 /2 and I1 Y2 years of age, this final admission being shortly after referral to our service. At the age of 12 years, the skin lesions resolved during a holiday to Pakistan, and the only therapy used was topical mustard oil. On return to Britain she was well, so she was discharged from our clinic. At Correspondence to: Professor T J David for 2 days. One week later, BCG was administered. Two days later, generalized pruritus developed and progressively worsened. Within 2 weeks of vaccination, she had widespread and severely inflamed and weeping skin lesions affecting the face, trunk and limbs. She was treated in hospital with a potent topical steroid ointment (fluticasone propionate 0.05%), and after some initial improvement was discharged home 4 days later. Readmission was required 2 weeks later because of pain from the severely inflamed skin lesions, which prevented walking or sitting. At the left forearm Mantoux site a 4 cm diameter erythematous lesion was noted, and a 1 cm tender swollen nodule at the BCG vaccination site. She was treated initially with a potent topical steroid ointment (fluticasone propionate 0.05%), and then changed to a moderately potent steroid ointment (fluocinolone acetonide 0.00625%) before being discharged home after 5 days. She was not seen for a further 5 months; then, after her skin lesions had been quiescent, she required admission to hospital for an acute exacerbation of atopic dermatitis attributed to bacterial skin infection. Her case was reported to the Committee on Safety of Medicines.
DISCUSSION
The Department of Health's book on immunization advises that 'BCG should not be given to individuals with generalized septic skin conditions' and 'if eczema exists, an immunization site should be chosen that is free from skin lesions'1. In the two cases reported here, severe exacerbation of pre-existing atopic dermatitis followed BCG vaccination. Cause and effect cannot be proved in these two cases, but other likely triggers were not noted, and the exacerbations were relatively resistant to treatment. When a child has active atopic dermatitis skin lesions we now warn parents that BCG vaccination may be associated with worsening; ifthe patient is not at special risk ofacquiring tuberculosis, we suggest that vaccination be deferred.
How might BCG worsen atopic dermatitis? CD4+ T cells, so-called T helper (Th) cells, can be further subdivided into Thl and Th2 subsets as defined by their patterns of cytokine secretion. Thl cells characteristically secrete interleukin (IL)-2, interferon-gamma (IFN-y) and tumour necrosis factor (TNF), and mediate protective immunity against intracellular micro-organisms including Mycobacterium tuberculosis. Although the mode of action of BCG is not fully understood, in-vitro studies of human mononuclear cells suggest that it stimulates a Thl gammainterferon (y-IFN) rich cytokine profile, which later switches to a Th2 cytokine profile2.
Th2 cells secrete IL-4, IL-5 and IL-10, thus stimulating B cells, eosinophils and mast cells-responses which are beneficial in parasitic infestation but which are also thought to mediate the tissue damage seen in patients with atopic dermatitis. It is regarded as a Th2 disease, with an increased IL-4: y-IFN ratio. While IL-4 predominates in acute skin lesions, chronic lesions express IL-53,4. A switch from the Th2 profile to additional Thl cytokine profile with chronicity has been proposed.
Although such switching of cytokine profiles with time, described both in atopic dermatitis and after BCG, is one possible explanation in these two cases, the divergence of Thl and Th2 cells is believed to be regulated chiefly by the innate immune response, at the outset of exposure to an infection or immunization. Cytokine profile influences Th cell differentiationS'6. IL-12 produced by macrophages is an early inducer of Thl cells while IL-4, from an unknown source, induces Th2 cells. Consequently, in normal individuals, including most atopic dermatitis patients, macrophages exposed to BCG secrete IL-12 and induce the Thl cytokine profile.
In the cases described here, we hypothesize that genetic influences, or some other form of susceptibility, have resulted in IL-4 production from the outset and encouraged a Th2 cytokine profile from either CD4+ or CD8+ lymphocytes. Activated lymphocytes also migrate preferentially to inflamed skin in atopic dermatitis, the tissue tropism being imparted by adhesion molecules selectively expressed on the cells. BCG, acting as a superantigen, may induce expression of cutaneous lymphocyte associated (CLA) antigen on T cells, with such CLA+ cells preferentially accumulating in inflamed skin. The cutaneous tropism of CLA+ T lymphocytes, or either CD4+ or CD8+ phenotype, secreting the Th2 cytokine (IL-4, IL-5, IL-6, IL-10) profile, may explain the flare-up of atopic dermatitis after BCG immunization.
